{"id":455349,"date":"2021-03-10T17:18:18","date_gmt":"2021-03-10T22:18:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=455349"},"modified":"2021-03-10T17:18:18","modified_gmt":"2021-03-10T22:18:18","slug":"veracyte-commends-new-uspstf-lung-cancer-screening-guidelines","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/","title":{"rendered":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines"},"content":{"rendered":"

<\/p>\n

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc<\/a>. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for current and former smokers to begin screening from 55 to 50 years and reduces smoking intensity \u2013 from a 30 \u201cpack-year\u201d history to 20. The independent expert panel\u2019s final recommendations appear online in the Journal of the American Medical Association<\/a><\/i>and are expected to increase the number of people in the United States who are eligible for annual screening with low dose CT (LDCT) scans to nearly 15 million.\n<\/p>\n

\n\u201cWe commend the USPSTF for their new lung cancer screening recommendations, which will help ensure that more lives are saved through early detection,\u201d said Bonnie Anderson, Veracyte\u2019s chairman and chief executive officer. \u201cLung cancer is the leading cause of cancer death in the United States because too often the disease is found after it has spread and is less treatable. Expanding screening eligibility \u2013 as well as the number of people who actually undergo screening \u2013 will be key to saving lives.\n<\/p>\n

\n\u201cMuch work remains in the fight against lung cancer, including ensuring that physicians have optimal tools to help guide patient care when potentially cancerous lung nodules are found through screening. We are proud to be part of the healthcare sector that is utilizing novel genomic science to improve lung cancer early detection, diagnosis and treatment.\u201d\n<\/p>\n

\nVeracyte\u2019s Percepta\u00ae Genomic Sequencing Classifier is available to improve the diagnosis of potentially cancerous lung nodules found on CT scans. The company is developing a first-of-its-kind, noninvasive nasal swab test to help determine which patients with lung nodules should undergo additional diagnostic procedures and which can simply be monitored. Additionally, the company is developing a comprehensive genomic profiling test to inform treatment decisions at the time of diagnosis. Both tests are scheduled for introduction in the second half of 2021.\n<\/p>\n

About Lung Cancer<\/b><\/p>\n

\nLung cancer is the deadliest cancer globally, killing more than 1.75 million people worldwide each year, according to the World Health Organization. Early detection is key, with a five-year survival rate of nearly 60 percent when the cancer is found early, compared to six percent when it is found at a later stage, according to the American Lung Association. Lung nodules are typically the first sign of lung cancer. While the vast majority of lung nodules ultimately prove to be benign, physicians currently lack clear diagnostic tools to determine which patients have cancer and which do not. This can lead to unnecessary invasive biopsies, which are costly and risky, as well as to delayed diagnosis and treatment.\n<\/p>\n

About Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company\u2019s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company\u2019s tests in lung cancer, breast cancer, thyroid cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte\u2019s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).\n<\/p>\n

Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the development and benefits of our genomic diagnostic tests. Actual results may differ materially from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations and Item 1A \u2013 \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the SEC on February 22, 2021. A copy of these documents can be found at the Investors section of our website at www.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210310005981\/en\/<\/a><\/span><\/p>\n

Investor and Media Contact:<\/b><\/p>\n

\nTracy Morris
\n
Vice President of Corporate Communications
\n
& Investor Relations
\n
650-380-4413
\n
tracy.morris@veracyte.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Genetics Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for current and former smokers to begin screening from 55 to 50 years and reduces smoking intensity \u2013 from a 30 \u201cpack-year\u201d history to 20. The independent expert panel\u2019s final recommendations appear online in the Journal of the American Medical Associationand are expected to increase the number of people in the United States who are eligible for annual screening with low dose CT (LDCT) scans to nearly 15 million. \u201cWe commend the USPSTF for their new lung … <\/p>\n

Continue reading “Veracyte Commends New USPSTF Lung Cancer Screening Guidelines”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-455349","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVeracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for current and former smokers to begin screening from 55 to 50 years and reduces smoking intensity \u2013 from a 30 \u201cpack-year\u201d history to 20. The independent expert panel\u2019s final recommendations appear online in the Journal of the American Medical Associationand are expected to increase the number of people in the United States who are eligible for annual screening with low dose CT (LDCT) scans to nearly 15 million. \u201cWe commend the USPSTF for their new lung … Continue reading "Veracyte Commends New USPSTF Lung Cancer Screening Guidelines"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T22:18:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines\",\"datePublished\":\"2021-03-10T22:18:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/\"},\"wordCount\":792,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/\",\"name\":\"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-10T22:18:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk","og_description":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for current and former smokers to begin screening from 55 to 50 years and reduces smoking intensity \u2013 from a 30 \u201cpack-year\u201d history to 20. The independent expert panel\u2019s final recommendations appear online in the Journal of the American Medical Associationand are expected to increase the number of people in the United States who are eligible for annual screening with low dose CT (LDCT) scans to nearly 15 million. \u201cWe commend the USPSTF for their new lung … Continue reading \"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T22:18:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines","datePublished":"2021-03-10T22:18:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/"},"wordCount":792,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/","name":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-10T22:18:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210310005981r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-commends-new-uspstf-lung-cancer-screening-guidelines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Commends New USPSTF Lung Cancer Screening Guidelines"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=455349"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=455349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=455349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=455349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}